Systemic Lupus Erythematosus News Archive

Ustekinumab Effective in Phase 2 Study for Systemic Lupus Erythematosus

Ustekinumab Effective in Phase 2 Study for Systemic Lupus Erythematosus

Results from a phase 2 study suggest that ustekinumab might be an effective therapy in systemic lupus erythematosus.

Infectious, Noninfectious Postoperative Complications More Frequent in Patients With SLE

Infectious, Noninfectious Postoperative Complications More Frequent in Patients With SLE

Patients with systemic lupus erythematosus have a high risk for postoperative complications and mortality following major surgery compared with patients without SLE.

Patient-Reported Outcomes Predict Mortality in Systemic Lupus Erythematosus

Patient-Reported Outcomes Predict Mortality in Systemic Lupus Erythematosus

Patient-reported outcomes are independent predictors of mortality in systemic lupus erythematosus.

Improving Rates of Combination Pneumococcal Vaccination in Patients With SLE

Improving Rates of Combination Pneumococcal Vaccination in Patients With SLE

Vaccination rates in patients with systemic lupus erythematosus improved significantly after the implementation of a multifaceted intervention at a rheumatology practice.

Tacrolimus Possibly Beneficial Long Term in Lupus Nephritis

Tacrolimus Possibly Beneficial Long Term in Lupus Nephritis

Over a 5-year period, the drug was well tolerated and associated with significant declines in urinary protein-creatinine ratio and mean prednisolone dose.

Childhood-Onset Systemic Lupus Erythematosus Negatively Affects Quality of Life in Adulthood

Childhood-Onset Systemic Lupus Erythematosus Negatively Affects Quality of Life in Adulthood

Childhood-onset SLE has major effects on quality of life in adulthood.

Active SLE Disease Activity, Damage Linked to Greater Mortality

Active SLE Disease Activity, Damage Linked to Greater Mortality

The use of validated disease activity and damage metrics is important in the assessment of SLE.

Effects of Cigarette Smoking, Alcohol Consumption on SLE Risk in Black Women

Effects of Cigarette Smoking, Alcohol Consumption on SLE Risk in Black Women

Cigarette smoking was associated with an increased SLE risk and alcohol consumption was associated with decreased SLE risk.

Prolonged Antimalarial Exposure Increases Risk for Elevated Cardiac Biomarkers in SLE

Prolonged Antimalarial Exposure Increases Risk for Elevated Cardiac Biomarkers in SLE

Prolonged antimalarial therapy and persistent creatine phosphokinase elevation resulted in an increased risk for abnormal brain natriuretic peptide and cardiac troponin.

High Rate of Subclinical Myocardial Injury in Systemic Lupus Erythematosus

High Rate of Subclinical Myocardial Injury in Systemic Lupus Erythematosus

Patients with systemic lupus erythematosus have a high prevalence of subclinical myocardial injury, as evidenced by raised high-sensitive troponin levels.

Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions

Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions

Patients with early SLE had higher rates of unexplained fever than those with SLE-mimicking conditions.

Lupus Nephritis With Impaired Renal Function Linked to Atherosclerosis in SLE

Lupus Nephritis With Impaired Renal Function Linked to Atherosclerosis in SLE

Lupus nephritis in combination with impaired renal function is strongly associated with the presence of atherosclerosis in patients with systemic lupus erythematosus.

Outcomes of SLE-Associated Thrombotic Microangiopathy With Acquired ADAMTS13 Deficiency

Outcomes of SLE-Associated Thrombotic Microangiopathy With Acquired ADAMTS13 Deficiency

Researchers investigated the characteristics and outcomes of patients with systemic lupus erythematosus-associated thrombotic microangiopathy based on their ADAMTS13 inhibitor profiles.

Promising Antibody Markers Identified for aPL-Related Pregnancy Complications

Promising Antibody Markers Identified for aPL-Related Pregnancy Complications

The aPS/PT antibodies might represent markers of aPL-related pregnancy complications, such as intrauterine grown restriction and preeclampsia.

High Risk for Zoster in Cyclophosphamide-Treated SLE, Systemic Vasculitis

High Risk for Zoster in Cyclophosphamide-Treated SLE, Systemic Vasculitis

The incidence of zoster is high in systemic vasculitis and in patients with SLE exposed to intravenous cyclophosphamide.

Epidemiology, Clinical Characteristics of Systemic Sclerosis vs SSc-SLE Overlap Syndrome

Epidemiology, Clinical Characteristics of Systemic Sclerosis vs SSc-SLE Overlap Syndrome

Patients with SSc-SLE overlap syndrome were younger at diagnosis, had higher rates of pulmonary arterial hypertension, and less frequently had SSc cutaneous manifestations.

Depression Risk High in Cutaneous, Systemic Lupus Erythematosus

Depression Risk High in Cutaneous, Systemic Lupus Erythematosus

The risk for depression was increased significantly in patients with systemic lupus erythematosus and cutaneous lupus erythematosus.

Silent Cardiac Impairment May Be Present in New-Onset, Drug-Naive Systemic Lupus Erythematosus

Silent Cardiac Impairment May Be Present in New-Onset, Drug-Naive Systemic Lupus Erythematosus

Data indicate that drug-naive new onset systemic lupus erythematosus was likely to involve silent cardiac impairment.

Poor Preconceptional Cardiovascular Health Affects Pregnancy Outcomes in SLE

Poor Preconceptional Cardiovascular Health Affects Pregnancy Outcomes in SLE

Poor preconception cardiovascular health affects pregnancy outcomes in women with SLE.

Burden of Entheseal Sonographic Changes High in Patients With SLE

Burden of Entheseal Sonographic Changes High in Patients With SLE

The burden of entheseal sonographic changes was significantly higher in patients with SLE vs healthy participants, especially with respect to active inflammation.

Corticosteroid Use Linked to Risk for Osteonecrosis in Systemic Lupus Erythematosus

Corticosteroid Use Linked to Risk for Osteonecrosis in Systemic Lupus Erythematosus

Investigators sought to identify the risk factors for osteonecrosis and to identify the minimal investigations needed to monitor the risk for osteonecrosis in patients with systemic lupus erythematosus.

Examining the Prevalence, Characteristics of Monophasic Disease Course in SLE

Examining the Prevalence, Characteristics of Monophasic Disease Course in SLE

Researchers sought to assess the prevalence and characteristics of monophasic disease course in a defined cohort of patients with SLE.

Comparing Factors Associated With Tubulointerstitial Inflammation in Lupus Nephritis

Comparing Factors Associated With Tubulointerstitial Inflammation in Lupus Nephritis

Routinely available serologic markers have no correlation with tubulointerstitial damage in patients with lupus nephritis.

Erythrocyte-Bound C4d May Be Useful for SLE Disease Monitoring

Erythrocyte-Bound C4d May Be Useful for SLE Disease Monitoring

Erythrocyte-bound C4d may be useful in monitoring systemic lupus erythematosus.

Poverty, Neighborhood May Affect Outcomes in Systemic Lupus Erythematosus

Poverty, Neighborhood May Affect Outcomes in Systemic Lupus Erythematosus

Outcomes in systemic lupus erythematosus are largely influenced by level of poverty, type of neighborhood of residence, and chronic stress.

Examining Trends of Histologic Presentation, Renal Outcomes in Lupus Nephritis

Examining Trends of Histologic Presentation, Renal Outcomes in Lupus Nephritis

Investigators sought to evaluate changes in demographic, clinical, and histologic presentation in patients with lupus nephritis between 1970 and 2016.

Anti-dsDNA Antibodies Correlated With Clinical, Laboratory Parameters in SLE

Anti-dsDNA Antibodies Correlated With Clinical, Laboratory Parameters in SLE

Female patients with systemic lupus erythematosus who had musculoskeletal symptoms or positive antiphospholipid antibodies demonstrated higher titers of anti-double-stranded DNA antibodies.

Increased Arterial Stiffness Observed in Patients With Systemic Lupus Erythematosus

Increased Arterial Stiffness Observed in Patients With Systemic Lupus Erythematosus

Patients with systemic lupus erythematosus exhibit increased central arterial stiffness compared with a healthy control population.

Pain, Cognitive Dysfunction in SLE Mediated by Sleep Disturbance, Depression

Pain, Cognitive Dysfunction in SLE Mediated by Sleep Disturbance, Depression

The relationship between pain and cognitive dysfunction was explained by sleep disturbance and depressive symptoms.

Bisphosphonate, Vitamin D Combination Therapy May Prevent Atherosclerosis in SLE

Bisphosphonate, Vitamin D Combination Therapy May Prevent Atherosclerosis in SLE

Bisphosphonates and vitamin D may help prevent atherosclerosis in patients with systemic lupus erythematosus.

ACR Provisional Criteria: Global Flares in Childhood-Onset SLE

ACR Provisional Criteria: Global Flares in Childhood-Onset SLE

Provisional criteria for global flares in patients with childhood-onset systemic lupus erythematosus are now available from the ACR.

Effects of SLE Diagnosis Examined in Antiphospholipid Antibody-Positive Patients

Effects of SLE Diagnosis Examined in Antiphospholipid Antibody-Positive Patients

Researchers compared the clinical, laboratory, and treatment characteristics of antiphospholipid antibody-positive patients with or without SLE.

Repeat Antibody Testing May Be Unnecessary for Some Patients With SLE

Repeat Antibody Testing May Be Unnecessary for Some Patients With SLE

Data show that anti-ENA results change infrequently, especially following 1 or more negative tests.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

Belimumab Effective for Hypocomplementemic, Anti-dsDNA-Positive SLE

Belimumab Effective for Hypocomplementemic, Anti-dsDNA-Positive SLE

Weekly belimumab treatment was safe and effective and superior to placebo for reducing disease activity over 52 weeks in patients who were hypocomplementemic and anti-dsDNA positive.

Comparing Statin Prescriptions, Lipid Testing in SLE vs Diabetes

Comparing Statin Prescriptions, Lipid Testing in SLE vs Diabetes

Researchers investigated whether patients with SLE receive lipid testing and statin prescriptions comparably with patients with diabetes.

Incident Proteinuria in SLE May Be Predicted by Certain Clinical, Serological Manifestations

Incident Proteinuria in SLE May Be Predicted by Certain Clinical, Serological Manifestations

Certain clinical and serological markers were predictive of future incident proteinuria in patients with systemic lupus erythematosus.

Lupus Is a Leading Cause of Death in Young Women

Lupus Is a Leading Cause of Death in Young Women

Systemic lupus erythematosus is among the top 20 leading causes of death in women between the ages of 5 and 64 years in the United States.

Identifying Social Determinants of Mortality in Systemic Lupus Erythematosus

Identifying Social Determinants of Mortality in Systemic Lupus Erythematosus

Investigators suggest several mechanisms for the contribution of poverty to high mortality rates in patients with systemic lupus erythematosus.

Quality of SLE Care Assessed in Specialized Lupus vs General Rheumatology Clinic

Quality of SLE Care Assessed in Specialized Lupus vs General Rheumatology Clinic

Researchers compared the quality of care received by patients with systemic lupus erythematosus in 2 settings within the same academic institution.

Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA

Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA

The Epstein-Barr virus EBNA2 protein and many coclustering human transcription factors occupied nearly half of SLE risk loci.

Metabolic Syndrome Frequency Assessed in Systemic Lupus Erythematosus

Metabolic Syndrome Frequency Assessed in Systemic Lupus Erythematosus

The frequency of metabolic syndrome among patients with SLE was approximately 45%.

Efficacy of Blisibimod Therapy Evaluated in Systemic Lupus Erythematosus

Efficacy of Blisibimod Therapy Evaluated in Systemic Lupus Erythematosus

Blisibimod was effective in patients with SLE in terms of steroid reduction, decreased proteinuria, and improvement in serological markers.

Ubiquitination in NETs May Affect Adaptive Immune Responses in SLE

Ubiquitination in NETs May Affect Adaptive Immune Responses in SLE

Neutrophil extracellular traps contain ubiquitinated proteins with a lower expression of polyubiquitinated proteins in patients with SLE.

Women With SLE Become Pregnant More Easily vs Women With Rheumatoid Arthritis

Women With SLE Become Pregnant More Easily vs Women With Rheumatoid Arthritis

Researchers examined differences in the ability to get pregnant in women with systemic lupus erythematosus and rheumatoid arthritis.

Ofatumumab Safe, Effective for B Cell Depletion in Rituximab-Intolerant SLE

Ofatumumab Safe, Effective for B Cell Depletion in Rituximab-Intolerant SLE

Ofatumumab was a well-tolerated, safe, and effective alternative to rituximab for B cell depletion therapy.

Novel Gene Variants Associated With CVD Identified in Patients With SLE and RA

Novel Gene Variants Associated With CVD Identified in Patients With SLE and RA

The IL-19 risk allele is associated with stroke and myocardial infarction in patients with systemic lupus erythematosus and rheumatoid arthritis, but not in the general population.

Examining Remission Status as a Predictor of Long-Term Renal Survival in Lupus Nephritis

Examining Remission Status as a Predictor of Long-Term Renal Survival in Lupus Nephritis

Remission status was a significant and useful predictor of renal survival, in patients with lupus nephritis.

Autoimmune Reactivity to Malondialdehyde in SLE Linked to High Disease Activity, Lupus Nephritis

Autoimmune Reactivity to Malondialdehyde in SLE Linked to High Disease Activity, Lupus Nephritis

Researchers investigated serum IgG anti-MDA expression and associations with disease activity in patients with systemic lupus erythematosus.

Examining Lupus Low Disease Activity State as an SLE Outcome Measure

Examining Lupus Low Disease Activity State as an SLE Outcome Measure

Results from the MUSE trial show that lupus low disease activity state attainment in patients with systemic lupus erythematosus is a clinically meaningful disease outcome measure.

Higher Rate of Atrial Fibrillation in Men With Systemic Lupus Erythematosus

Higher Rate of Atrial Fibrillation in Men With Systemic Lupus Erythematosus

Researchers used phenotype-wide association studies to uncover associations in men and women with systemic lupus erythematosus.

Systemic Lupus Erythematosus Disease Flares Increase During, Shortly After Pregnancy

Systemic Lupus Erythematosus Disease Flares Increase During, Shortly After Pregnancy

Researchers found that disease flare incidence in women with SLE increased during pregnancy and within 3 months postpartum.

Mortality, ESRD Incidence Measured in Men vs Women With Lupus Nephritis

Mortality, ESRD Incidence Measured in Men vs Women With Lupus Nephritis

No significant differences were observed in the incidence of ESRD and mortality among men vs women with lupus nephritis.

Childhood-Onset SLE Often Results in Damage to Several Organ Systems

Childhood-Onset SLE Often Results in Damage to Several Organ Systems

Disease damage in patients with childhood-onset SLE is common, even with relatively short disease durations.

Epratuzumab in SLE With Associated Sjogren Syndrome Improved SLE Disease Activity

Epratuzumab in SLE With Associated Sjogren Syndrome Improved SLE Disease Activity

Epratuzumab improved systemic lupus erythematosus disease activity in patients with associated Sjogren syndrome.

Few SLE Patients Receive Retinal Examinations With Hydroxychloroquine Initiation

Few SLE Patients Receive Retinal Examinations With Hydroxychloroquine Initiation

Researchers examined the proportion of Medicaid patients with systemic lupus erythematosus who receive baseline retinal examinations when initiating treatment with hydroxychloroquine.

Short-Form Patient-Reported Outcomes Tool Effective in SLE

Short-Form Patient-Reported Outcomes Tool Effective in SLE

The PROMIS10 patient-reported outcome measure is a valid and reliable tool in routine systemic lupus erythematosus care.

Raynaud Phenomenon, Migraine Linked to aPS/PT Antibodies in Primary Antiphospholipid Syndrome

Raynaud Phenomenon, Migraine Linked to aPS/PT Antibodies in Primary Antiphospholipid Syndrome

In patients with primary antiphospholipid syndrome, the presence of phosphatidylserine/prothrombin complex antibodies is associated with Raynaud phenomenon and migraine.

Complement Pathway Activation Linked to Adverse Pregnancy Outcomes in Women With SLE

Complement Pathway Activation Linked to Adverse Pregnancy Outcomes in Women With SLE

Complement pathway activation is associated with adverse pregnancy outcomes in women with systemic lupus erythematosus or antiphospholipid antibodies.

Predictors of Disability Assessed in Childhood-Onset Systemic Lupus Erythematosus

Predictors of Disability Assessed in Childhood-Onset Systemic Lupus Erythematosus

Data from the CARRA Legacy Registry show disability is common in patients with childhood-onset SLE.

Smoking Status Linked to Risk for Anti-Double Stranded DNA SLE Subtype

Smoking Status Linked to Risk for Anti-Double Stranded DNA SLE Subtype

Smoking is associated with risk for development of the anti-double-stranded DNA positive subtype of systemic lupus erythematosus.

Effects of Cerebrovascular Morbidity on Quality of Life in SLE

Effects of Cerebrovascular Morbidity on Quality of Life in SLE

The frequency, attribution, clinical, and autoantibody status of patients with lupus who developed cerebrovascular events are reported in this study.

Does SLE Increase the Risk for Perioperative Major Adverse Cardiovascular Events?

Does SLE Increase the Risk for Perioperative Major Adverse Cardiovascular Events?

Future research should look to improve perioperative management in people with systemic lupus erythematosus.

Nitrated Nucleosome Levels Linked to Neuropsychiatric Events in Systemic Lupus Erythematosus

Nitrated Nucleosome Levels Linked to Neuropsychiatric Events in Systemic Lupus Erythematosus

At this time, no serological test can distinguish neuropsychiatric events resulting from SLE activity from events resulting from other causes.

Association Between Maternal Systemic Lupus Erythematosus and Asthma in Offspring

Association Between Maternal Systemic Lupus Erythematosus and Asthma in Offspring

The risk for asthma may be increased in children born to mothers with systemic lupus erythematosus during pregnancy.

Comparable Risk for Atherosclerosis in Antiphospholipid Syndrome and Diabetes

Comparable Risk for Atherosclerosis in Antiphospholipid Syndrome and Diabetes

Patients with primary antiphospholipid syndrome and systemic lupus erythematosus-associated antiphospholipid syndrome have an almost 2.5-fold risk for development of atherosclerotic plaques in carotid and femoral arteries compared with healthy control patients.

Predictors of Incident Proteinuria in Systemic Lupus Erythematosus

Predictors of Incident Proteinuria in Systemic Lupus Erythematosus

Older patients with SLE are at a low risk for the development of proteinuria.

Failure to Achieve Low Disease Activity Linked to Early Damage Accrual in SLE

Failure to Achieve Low Disease Activity Linked to Early Damage Accrual in SLE

Lupus low disease activity state has been shown to be achievable and negatively associated with early damage accrual.

Consistent Antimalarial Intake in First 5 Years of SLE Linked to Improved Prognosis

Consistent Antimalarial Intake in First 5 Years of SLE Linked to Improved Prognosis

Investigators evaluated long-term outcomes with antimalarial use and organ damage, flares, disease activity, glucocorticoid use, and antimalarial associated retinopathy.

Evidence-Based Recommendations for the Diagnosis, Treatment of Childhood-Onset Lupus Nephritis

Evidence-Based Recommendations for the Diagnosis, Treatment of Childhood-Onset Lupus Nephritis

The SHARE initiative has formulated evidence-based recommendations for the diagnosis and treatment of lupus nephritis childhood-onset lupus nephritis.

Maternal Systemic Lupus Erythematosus May Increase Risk for Childhood Asthma

Maternal Systemic Lupus Erythematosus May Increase Risk for Childhood Asthma

Maternal systemic lupus erythematosus during pregnancy is associated with increased risk for asthma in children.

Switching Antimalarial Agent in Patients With Cutaneous Lupus Erythematosus

Switching Antimalarial Agent in Patients With Cutaneous Lupus Erythematosus

Switching from 1 antimalarial agent to a second may be beneficial in patients with cutaneous lupus erythematosus.

Atacicept Effective for Systemic Lupus Erythematosus Activity, Severity

Atacicept Effective for Systemic Lupus Erythematosus Activity, Severity

Atacicept may be safe and effective for lowering disease activity and severity in patients with active systemic lupus erythematosus.

Systemic Lupus Erythematosus Mortality Rates Decreased in the United States From 1968 to 2013

Systemic Lupus Erythematosus Mortality Rates Decreased in the United States From 1968 to 2013

Rates of SLE mortality have declined, but remain high relative to non-SLE mortality.

Active Nephritis in Active SLE: Identification of a New Biomarker

Active Nephritis in Active SLE: Identification of a New Biomarker

Anti-ficolin-2 autoantibodies may represent a biomarker for renal manifestations in patients with active systemic lupus erythematosus.

Systemic Lupus Erythematous Responder Index: Primary Drivers

Systemic Lupus Erythematous Responder Index: Primary Drivers

The efficacy variables with the greatest effect on systemic lupus erythematous (SLE) Responder Index responder status in clinical trials include SLE Disease Activity Index improvement, concomitant medication adherence, and trial completion.

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

The recurrence of fetal cardiac conduction disturbances in the fetuses of women expressing anti-Ro/SSA antibodies may be influenced by the season of the year and maternal age.

Impact of Remission, Low Disease Activity on Outcomes in Lupus

Impact of Remission, Low Disease Activity on Outcomes in Lupus

While a treat to target strategy has been proposed for managing SLE, the impact of possible disease outcomes has not been fully evaluated.

Smoking May Be Linked to Pathogenesis of Anti-double Stranded DNA in SLE

Smoking May Be Linked to Pathogenesis of Anti-double Stranded DNA in SLE

Current smoking and >10 pack-years of smoking have demonstrated a strong and specific association with an increased risk for occurrence of anti-double-stranded DNA systemic lupus erythematosus.

In SLE, Medication Non-Adherence, Depression Are Prevalent

In SLE, Medication Non-Adherence, Depression Are Prevalent

In patients with SLE, 62.1% did not adhere to their medication regimens and 35% of patients demonstrated a depressed mood.

Trauma Associated With Incident Systemic Lupus Erythematosus in Women

Trauma Associated With Incident Systemic Lupus Erythematosus in Women

Identification of the biologic pathways by which psychosocial trauma may increase a woman's risk for autoimmune disorders is critical and may offer greater insight into disease etiology and strategies for prevention.

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

The high prevalence of cognitive impairment in patients with SLE creates a need for a reliable and cost-effective screening tool.

Comprehensive Methods Work to Determine SLE Incidence and Prevalence

Comprehensive Methods Work to Determine SLE Incidence and Prevalence

Research confirmed the increased burden of SLE in black, Asian, and Hispanic women compared with white women.

Hydroxychloroquine Effects on Cholesterol Levels in Systemic Lupus Erythematosus

Hydroxychloroquine Effects on Cholesterol Levels in Systemic Lupus Erythematosus

Research revealed that hydroxychloroquine is associated with reduced LDL-C and total cholesterol levels in patients with lupus.

Patients With SLE at Higher Risk of Developing Metabolic Syndrome

Patients With SLE at Higher Risk of Developing Metabolic Syndrome

More than 25% of SLE patients also have metabolic syndrome.

Complement System a Contributor to Lupus Clinical Manifestations

Complement System a Contributor to Lupus Clinical Manifestations

Mannose-binding lectin of the complement system may contribute to the development of clinical manifestations in SLE.

SHARE Launches Childhood-Onset Systemic Lupus Erythematosus Initiative

SHARE Launches Childhood-Onset Systemic Lupus Erythematosus Initiative

The SHARE initiative established guidelines on cSLE, which is a rare disorder.

Diagnosis and Treatment of Childhood Lupus Nephritis: SHARE Recommendations

Diagnosis and Treatment of Childhood Lupus Nephritis: SHARE Recommendations

The development of lupus nephritis is associated with significant morbidity and mortality.

CVD Prevention Counseling Decreases CVD Risk Factor Prevalence in SLE

CVD Prevention Counseling Decreases CVD Risk Factor Prevalence in SLE

This study finds that a cardiovascular disease prevention counseling program decreases the prevalence of cardiovascular disease risk factors in patients with systemic lupus erythematosus.

B-Cell Depletion Predicts Rituximab Response in Systemic Lupus Erythematosus

B-Cell Depletion Predicts Rituximab Response in Systemic Lupus Erythematosus

Rituximab non-responders may still be amenable to B-cell targeted therapies, such as ofatumumab or obinutuzumab.

No Increased Risk of SLE Found With Current Statin Use

No Increased Risk of SLE Found With Current Statin Use

The risk of developing SLE in current statin users aged ≥40 years was no different than that in nonusers.

Venetoclax Safe, Effective in Women With Systemic Lupus Erythematosus

Venetoclax Safe, Effective in Women With Systemic Lupus Erythematosus

Use of the anti-apoptotic protein B-cell lymphoma 2 inhibitor venetoclax reduced total lymphocyte and disease-relevant B cells in women with SLE.

Systemic Lupus Erythematosus Activity in Pregnant Women Increases After Childbirth

Systemic Lupus Erythematosus Activity in Pregnant Women Increases After Childbirth

SLE was low to absent in pregnant women during conception and pregnancy, but increased after delivery.

SLE: New Candidate Criteria Drafted By Researchers

SLE: New Candidate Criteria Drafted By Researchers

Researchers have created a set of 21 candidate criteria for SLE as part of a multiphase development of a set of criteria for the disease.

Pediatric SLE Pulmonary Function Measures: FENO as Potential Biomarker

Pediatric SLE Pulmonary Function Measures: FENO as Potential Biomarker

FENO monitoring may provide a biomarker of disease activity and signify the emergence of pulmonary involvement in kids with SLE.

Hydroxychloroquine Plus Low-Dose Aspirin Reduces Cardiovascular Events in Systemic Lupus Erythematosus

Hydroxychloroquine Plus Low-Dose Aspirin Reduces Cardiovascular Events in Systemic Lupus Erythematosus

Long-term hydroxychloroquine use, combined with low-dose aspirin, protected against thrombosis in patients with systemic lupus erythematosus.

Diffuse Alveolar Hemorrhage in SLE Associated With Serious Disease Flare

Diffuse Alveolar Hemorrhage in SLE Associated With Serious Disease Flare

This condition is associated with serious disease flare complicated by sepsis and a high mortality rate.

Risk Factors for Depression in Patients With Childhood-Onset Lupus

Risk Factors for Depression in Patients With Childhood-Onset Lupus

Increased disease activity, poorer physical functioning, and lower education attainment were major predictors for depression in adulthood.

Biomarkers of Pulmonary Arterial Hypertension Risk in SLE

Biomarkers of Pulmonary Arterial Hypertension Risk in SLE

Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with systemic lupus erythematosus.

Patients With Systemic Lupus Erythematosus and Cognitive Dysfunction Prevalence

Patients With Systemic Lupus Erythematosus and Cognitive Dysfunction Prevalence

MOCA is more effective than the Mini-Mental State Examination at detecting cognitive dysfunction.

Sign Up for Free e-newsletters